Oncotech

15501 Red Hill Avenue
Tustin, CA 92780
Phone: (800) 576-6326
Fax: (714) 566-0421

Client Services
Phone: (800) 662-6832
Fax: (714) 566-0423

Oncotech is Currently Engaged in Clinical Studies
with Several Major Institutions Worldwide

Clinical Trials
•	Oncotech is currently involved in clinical studies with several leading cancer research institutions. (PDF Download)
Research
•	Chemotherapy Resistance and Oncogene Expression in Non-Small Cell Lung Cancer
•	Biomarker Expression Profiles in Primary versus Metastatic Colorectal Tumors
•	In Vitro Testing of Drug Cross-Resistance to Improve Standard Combination Chemotherapy Selection in Colorectal Cancer
•	Differential Gene Expression Associated with Early Tumor Recurrence and Long Disease Free Survival in Early Stage Non-Small Cell Lung Cancer
•	Biomarker and In Vitro Chemoresistance Profiles of Undifferentiated Ovarian Cancers
•	In Vitro Drug Resistance Profiles and Biomarker Expression in 414 Freshly Resected Esophageal Cancer Specimens
•	In Vitro Drug Resistance Profiles Correlate with DNA Ploidy and p53 Expression in 3,106 Endometrioid and Papillary Serous Adenocarcinomas of the Uterus
•	In Vitro Drug Resistance in Non-Diploid and p53-Positive Non-Small Cell Lung Cancer: An EDR Study on 578 Freshly Resected Adenocarcinomas
•	Identification of Amplifications and Deletions in Taxol Resistant Ovarian Cancer by Comparative Genomic Hybridization Screening
•	Association of DNA Ploidy and p53 Expression with 5-FU, CPT-11, and Oxaliplatin Resistance in the EDR Assay: A Study of 1,271 Colon Adenocarcinomas
•	In Vitro Chemotherapy Drug Resistance Profiles in Colon Cancer: Analysis of 1,271 Cases of Colonic Adenocarcinoma
•	Morphological and Immunohistochemical Assessment of In Vitro Cell Proliferation of Fresh Human Tumor Tissues in an Agarose-Based Assay
•	A 96-well Soft Agar Based Assay for Testing Cell Lines and Tumors
•	Detecting Altered Expression and Activation of Signaling Pathways in Cisplatin Resistant Ovarian Cancer
•	Correlating Signal Transduction Protein Kinase Levels, SNPs and Drug Resistance in Human Melanoma
•	In Vitro Extreme Chemotherapy Resistance Patterns for Resected Non-Small Cell Lung Cancer
•	Optimization of protocols and screening of Topoisomerase II-alpha for SNPs that predict response to etoposide and doxorubicin.
•	Antiangiogenesis Activity of Buthionine Sulfoximine (BSO) Related to Glutathione Depletion and Dynein Overexpression
•	CD117/KIT Expression and Alkylator Resistance in Solid Tumors
•	In Vitro Dosing Schedules in Breast and Ovarian Cancer and the Relationship with Topoisomerase I Expression
•	In Vitro and Ex Vivo Activity of SDX-105 (Bendamustine) in Drug-Resistant Lymphoma cells
•	The Possible Role of Chemoresistance Testing in the Era of Post Surgical Adjuvant Chemotherapy for Non-Small Cell Lung Cancer (NSCLC)
•	A Prospective Blinded Study of Predictive Value of Extreme Drug Resistance Assay in Patients Receiving CPT-11 for Recurrent Glioma
•	In Vitro Chemoresistance and Biomarker Profiles are Unique for Histologic Subtypes of Epithelial Ovarian Cancer
•	Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy
•	In Vitro Activity of Tarceva� in Primary Lung And Colon Cancer Cells
•	Correlation of Tumor-Associated Biomarkers with In Vitro Drug Response (IVDR) in Malignant Gliomas
•	Endothelial Cells Co-Cultured with Breast or Ovarian Cancer Demonstrated Differential Gene Expression and Apoptotic Response
•	Distinct Intrinsic and Dynamic Gene Expression Profiles Associated with Taxane Response in Breast and Ovarian Cancer
•	Enhanced Antimelanoma Activity After Exposure to BSO in Combination with Disulfiram
•	Application of Surface-Enhanced Laser Desorption/Ionization Technology to Discover Ovarian Cancer Biomarkers for Early Detection and Individualized Treatment
•	Association Between In Vitro Platinum Resistance in the EDR Assay and Clinical Outcomes for Ovarian Cancer Patients
•	In vitro assay-assisted treatment selection for women with breast or ovarian cancer
•	The Relationship of Molecular Markers of p53 Function and Angiogenesis to Prognosis of Stage I Epithelial Ovarian Cancer
•	Differential Gene Expression Analysis Genetically Fingerprints Tumors of Unknown Primary
•	Antiangiogenesis Effects of Docetaxel and L-Buthionine-S, R-Sulfoximine (BSO) on Tumor Derived Vascular Endothelial Cells
•	In Vitro Drug Response and Biomarker Profiles for Ovarian Cancer Specimens Obtained at Initial Debulking or after Neoadjuvant Chemotherapy (EORTC 55971)
•	Development of an in Vitro Chemo-Radiation Response Assay for Cervical Carcinoma
•	Survival and Response Rates in Refractory Ovarian Cancer Treated with Chemoresistance Assay Guided Chemotherapy
•	Gene Array Analysis of In Vitro Drug Response
•	Breast cancer survival and in vitro tumor response in the extreme drug resistance assay
•	Gene Array Analysis of Endothelial Cells Isolated from Human Tumors: A New Approach to the Development of Antiangiogenesis Therapies
•	In Vitro Drug Resistance Patterns in Epithelial Ovarian Cancer
•	Significant Association between Angiogenesis Index and Survival in Colorectal Cancer
•	High Throughput Screening for MDR1 Substrate Specificity Using the MDR1 Shift Assay